Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma

  • Gaku Takano
  • , Shinichi Esaki
  • , Fumi Goshima
  • , Atsushi Enomoto
  • , Yoshimi Hatano
  • , Haruka Ozaki
  • , Takahiro Watanabe
  • , Yoshitaka Sato
  • , Daisuke Kawakita
  • , Shingo Murakami
  • , Takayuki Murata
  • , Yukihiro Nishiyama
  • , Shinichi Iwasaki
  • , Hiroshi Kimura

Research output: Contribution to journalArticlepeer-review

Abstract

Immune responses can enhance anti-tumor capacity of viruses; therefore, full investigation of oncolytic virotherapy requires use of non-immunodeficient mice. Since no commercial cell lines are available, we established a murine model for oral carcinoma and evaluated oncolytic activity of HF10, naturally attenuated herpes simplex virus, in vitro and in vivo.

Original languageEnglish
Pages (from-to)220-227
Number of pages8
JournalMolecular Therapy Oncolytics
Volume20
DOIs
Publication statusPublished - 26-03-2021
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma'. Together they form a unique fingerprint.

Cite this